Vimta Labs Ltd Q2 FY26: ₹102 Cr Revenue, ₹19.9 Cr PAT, Bonus Shares & Biologics Gamble — From Test Tubes to Test Millions!
1. At a Glance
Vimta Labs — the Hyderabad-based lab that used to quietly test your food, pharma, and even your pollution levels — has suddenly turned into that overachieving nerd who just got a makeover and now hangs out with biotech kids.
For Q2 FY26, the company reported revenue of ₹1,045 million (₹104.5 crore), up 20.2% YoY, while PAT stood at ₹199 million (₹19.9 crore), a solid 17% jump YoY. Operating margin came in at a fat 35.3%, the kind usually reserved for software companies and drug smugglers.
Market cap? ₹3,039 crore. Stock P/E? 40.7x. Return on capital? A spicy 25.2%. Debt? A mere ₹6.8 crore — less than what some CEOs spend on their weekend golf carts.
And if that wasn’t enough, Vimta’s Board dropped not one, but two dopamine bombs this year:
A 1:1 Bonus Issue (June 2025)
A new Biologics CDMO venture (April 2025)
From testing food for contamination to testing molecules for billion-dollar clients — Vimta’s transformation smells more like a biotech thriller than a sleepy testing lab story.
2. Introduction
Back in the 90s, Vimta Labs started as the “guy who tests your water and snacks.” Fast forward to 2025, and the same Vimta now wants to be your biotech CDMO partner, rubbing shoulders with Syngene and Lonza. Talk about a glow-up.
The last two years have been a sequence of plot twists: they sold off their Clinical Diagnostics business to Thyrocare, merged their wholly owned subsidiary Emtac Laboratories, bagged a ₹4.09 crore grant from the Ministry of Food Processing, and used the leftover time to file bonus shares like a flex.
Their Q2 FY26 numbers scream transformation — with revenue crossing ₹100 crore per quarter for the first time, and profit scaling to ₹20 crore. The lab that once tested your pesticides now tests molecules for multinational pharma clients.
Question for the reader — what’s more impressive? The 138% stock return in a year, or that they pulled it off while staying almost debt-free?
3. Business Model – WTF Do They Even Do?
Vimta Labs is like the scientific cousin of Infosys — instead of debugging code, they debug your drugs, your food, your water, and occasionally, your emissions.
Their operations run across four key verticals:
Life Sciences R&D Support
Drug discovery, preclinical, clinical and analytical testing for pharmaceutical and biotech firms.
Services include stability studies, method validation, bioanalytical research, and GLP-certified studies.
Basically, pharma giants outsource their headaches to Vimta, and Vimta invoices those headaches beautifully.
Food & Agriculture Testing
Tests everything from pesticide residue in fruits to plasticizers in food packaging.
Also does testing for electronics and electricals — because India loves combining completely unrelated industries.
Environmental Testing & Consultancy
Tests air, water, soil, and noise levels for industrial and government clients.
Conducts marine ecology and deep-ocean studies (probably the only Indian company that can find a shrimp and a sulphate in the same report).
Clinical Diagnostics (Exited in 2024)
Sold to Thyrocare in Aug 2024, freeing Vimta to focus on higher-margin B2B segments.
Lab Infrastructure:
Over 4 lakh sq. ft of ultra-modern lab space.
15 regional and satellite labs spread across India.
Certified under multiple international standards (NABL, GLP, ISO).
The new pivot? Biologics CDMO — a ₹50 crore investment to move into custom manufacturing for biologics and biosimilars. Basically, from “we’ll test your drug” to “we’ll make your drug.”
4. Financials Overview
Source table
Metric (₹ Cr)
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
104.5
85.0
98.0
20.2%
6.6%
EBITDA
36.9
30.0
34.0
23.0%
8.5%
PAT
19.9
17.0
19.0
17.0%
4.7%
EPS (₹)
4.47
3.82
4.24
17.0%
5.4%
When your lab margin is higher than Zomato’s delivery margin, you know you’re in a sweet spot. EBITDA at 35%+ shows Vimta’s strong operational grip — every test tube is paying rent.
5. Valuation Discussion – Fair Value Range
Let’s run the numbers like a cautious analyst with a sense of humour.
(a) P/E Method: EPS (TTM): ₹17.7 Industry P/E: 45.4x → Fair Value
